Hrvaška - hrvaščina - HALMED (Agencija za lijekove i medicinske proizvode)

krka - farma d.o.o., radnička cesta 48, zagreb, hrvatska - deksametazon - tableta - 40 mg - urbroj: svaka tableta sadrži 40 mg deksametazona

Hrvaška - hrvaščina - HALMED (Agencija za lijekove i medicinske proizvode)

krka - farma d.o.o., radnička cesta 48, zagreb, hrvatska - deksametazon - tableta - 8 mg - urbroj: svaka tableta sadrži 8 mg deksametazona

Evropska unija - hrvaščina - EMA (European Medicines Agency)

accord healthcare s.l.u. - lenalidomid - multipli mijelom - imunosupresivi - multiple myelomalenalidomide accord as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide accord as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) indiciran za liječenje odraslih bolesnika s ranije нелеченной multiplog mijeloma koji se ne oslanja transplantacije. akord леналидомид u kombinaciji s дексаметазоном indiciran za liječenje multiple myeloma kod odraslih pacijenata koji su primili barem jedan tečaj terapija. follicular lymphomalenalidomide accord in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Hrvaška - hrvaščina - HALMED (Agencija za lijekove i medicinske proizvode)

krka d.d., novo mesto, Šmarješka cesta 6, novo mesto, slovenija - natrijev deksametazonfosfat - otopina za injekciju / infuziju - 4 mg/ml - urbroj: jedna ampula od 1 ml sadrži 4 mg deksametazonfosfata (u obliku natrijevog deksametazonfosfata)

Hrvaška - hrvaščina - HALMED (Agencija za lijekove i medicinske proizvode)

krka d.d., novo mesto, Šmarješka cesta 6, novo mesto, slovenija - natrijev deksametazonfosfat - otopina za injekciju / infuziju - 8 mg/2 ml - urbroj: jedna ampula od 2 ml sadrži 8 mg deksametazonfosfata (u obliku natrijevog deksametazonfosfata)

Evropska unija - hrvaščina - EMA (European Medicines Agency)

sanofi winthrop industrie - isatuximab - multipli mijelom - antineoplastična sredstva - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.

Evropska unija - hrvaščina - EMA (European Medicines Agency)

mylan ireland limited - lenalidomid - multipli mijelom - imunosupresivi - multiple myelomalenalidomide mylan as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide mylan as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant. lenalidomide mylan in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide mylan in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1-3a).

Evropska unija - hrvaščina - EMA (European Medicines Agency)

krka, d.d., novo mesto  - lenalidomide hydrochloride hydrate - multiple myeloma; lymphoma, follicular; myelodysplastic syndromes - imunosupresivi - multiple myelomalenalidomide krka d. as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) indiciran za liječenje odraslih bolesnika s ranije нелеченной multiplog mijeloma koji se ne oslanja transplantacije. lenalidomide krka d. in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka d. as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. follicular lymphomalenalidomide krka d. in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Evropska unija - hrvaščina - EMA (European Medicines Agency)

stemline therapeutics b.v. - selinexor - multipli mijelom - antineoplastična sredstva - nexpovio is indicatedin combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

Hrvaška - hrvaščina - HALMED (Agencija za lijekove i medicinske proizvode)

labormed - pharma s.a., 44b theodor pallady blvd, 3rd district, bucharest, rumunjska - lenalidomidum - kapsula, tvrda - 10 mg - urbroj: jedna kapsula sadrži 10 mg lenalidomida